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Mutations in p53, although frequent in human can-
cers, have not been implicated in telomere-related
syndromes. Here, we show that homozygous mutant
mice expressing p53D31, a p53 lacking the C-terminal
domain, exhibit increased p53 activity and suffer
from aplastic anemia and pulmonary fibrosis, hall-
marks of syndromes caused by short telomeres.
Indeed, p53D31/D31 mice had short telomeres and
other phenotypic traits associated with the telomere
disease dyskeratosis congenita and its severe
variant the Hoyeraal-Hreidarsson syndrome. Hetero-
zygous p53+/D31 mice were only mildly affected, but
decreased levels of Mdm4, a negative regulator of
p53, led to a dramatic aggravation of their symptoms.
Importantly, several genes involved in telomere
metabolism were downregulated in p53D31/D31 cells,
including Dyskerin, Rtel1, and Tinf2, which are
mutated in dyskeratosis congenita, and Terf1, which
is implicated in aplastic anemia. Together, these data
reveal that a truncating mutation can activate p53
and that p53 plays a major role in the regulation of
telomere metabolism.
INTRODUCTION
Mutations in TP53, the gene encoding transcription factor p53,
are frequently observed in sporadic cancers (Nigro et al.,
1989), and germline TP53mutations cause the Li-Fraumeni syn-
drome of cancer predisposition (Malkin et al., 1990; Srivastava
et al., 1990). These and other findings established p53 as amajor
tumor suppressor (Lane and Levine, 2010). In recent years, how-
ever, p53 emerged as a protein with a wide variety of functions: it
is now thought to regulate longevity, fertility, and the production2046 Cell Reports 3, 2046–2058, June 27, 2013 ª2013 The Authorsof stem cells and is involved in diseases including diabetes and
several neurological disorders (Brady and Attardi, 2010).
Most p53 mutations in cancers affect the core DNA-binding
domain of the protein, altering its capacity to regulate transcrip-
tional target genes (Toledo and Wahl, 2006). Importantly, how-
ever, p53 contains a second DNA-binding domain in its carboxyl
terminus (Foord et al., 1991), whose role remains elusive (Hupp
et al., 1992; McKinney et al., 2004). Early studies suggested
that the p53 C-terminal domain (CTD), whose interaction with
DNA is not sequence dependent, acts as a negative regulator
of the core DNA-binding domain (Hupp et al., 1992). However,
later reports concluded that p53 requires its CTD for efficient
recognition of target gene sequences (McKinney et al., 2004;
Tafvizi et al., 2011; Hamard et al., 2012; Kim et al., 2012). The
phosphorylation of C-terminal serines 378 and 392 was pro-
posed to increase p53 DNA binding (Hupp et al., 1992; Takenaka
et al., 1995), but only the latter was mutated and analyzed in vivo
(Bruins et al., 2004). Furthermore, posttranslational modifica-
tions of C-terminal lysines were proposed to be essential for
the regulation of p53 stability and activity, but mice with C-termi-
nal lysines mutated into arginines appeared similar to wild-type
(WT) mice (Feng et al., 2005; Krummel et al., 2005), except for
a hypersensitivity to g-irradiation (Wang et al., 2011a). Impor-
tantly, in vitro data suggested that a deletion of the p53 CTD,
or mutations of C-terminal lysines, might cause distinct pheno-
types because the CTD is required for an optimal interaction of
p53 with Mdm2, a ubiquitin ligase that regulates p53 stability
(Poyurovsky et al., 2010).
Here, we targeted a nonsensemutation at themouse Trp53 lo-
cus to evaluate the consequences of a deletion of the p53 CTD
in vivo. The results we obtained clearly demonstrate that a dele-
tion of the CTD leads to increased p53 activity. Most mice
expressing a p53 lacking the CTD died rapidly after birth and ex-
hibited features typical of telomere syndromes, including aplas-
tic anemia, lung fibrosis, and short telomeres. Consistent with
these observations, we found that p53 activation leads to
the downregulation of several genes involved in telomere
metabolism including Dyskerin, a gene frequently mutated in
dyskeratosis congenita (DC), the archetypal telomere syndrome
(Armanios and Blackburn, 2012). These data provide evidence
that p53 plays an important role in the regulation of telomere
metabolism.
RESULTS
Rationale for the Targeting of a Nonsense Mutation
Affecting the p53 CTD
In most in vitro studies, p53 mutants lacking the last 30–33 res-
idues were analyzed. These mutants lacked a region enriched in
basic residues (lysines, arginines, and histidines within residues
363–382 in human p53) and most if not all the C-terminal resi-
dues subject to posttranslational modifications (lysines, serines,
and threonines within residues 362–392 in human p53). How-
ever, they retained an intact tetramerization domain (within resi-
dues 326–355 in human p53) (Figure S1A). Here, we aimed to
analyze the consequences of a similar deletion of the p53 CTD
in vivo and, thus, to target a nonsense mutation leading to a
mouse p53 mutant that lacks the last 30–33 residues.
However, targeting a nonsense mutation at the murine Trp53
locus presented two possible obstacles. First, a mutation
removing the last 30–33 residues, within the penultimate exon
(exon 10), might cause nonsense-mediated mRNA decay. Sec-
ond, Trp53 encodes, from mutually exclusive final exons,
isoforms with two distinct CTDs: exon 11, used predominantly,
encodes the ‘‘classical’’ p53 protein, whereas exon AS (for alter-
native splicing) encodes mouse-specific isoforms with a shorter
C terminus (Arai et al., 1986). Therefore, although a mutation in
exon 11 encoding a protein with a deletion of at most 26 residues
would prevent mRNA degradation, we were concerned that it
might perturb mRNA splicing and lead to compensatory p53AS
overexpression (Figure S1B). These possibilities prompted us
to perform preliminary experiments in which constructs encod-
ing proteins with deletions of the last 26 (p53D26) or 31 (p53D31)
residues were targeted in mouse embryonic fibroblasts (MEFs)
by recombinase-mediated cassette exchange (RMCE) (Figures
S1C and S1D). Neither mutation led to measurable decreases
in p53 activity or p53 mRNA levels, but the mutation encoding
p53D26 was associated with a 9-fold increase in p53AS mRNAs
(Figures S1E–S1J). From these data, we decided to create a
mouse with a nonsense mutation deleting the last 31 residues.
p53D31/D31 MEFs Exhibit Increased p53 Activity
To generate amouse expressing p53D31 conditionally, we used a
targeting vector containing the mutation in exon 10 and tran-
scriptional Stops flanked by LoxP sites (LSL) upstream of coding
sequences (Figures 1A–1D). F1 intercrosses then produced
p53LSL-D31/LSL-D31 MEFs (Figure 1E). To analyze the effect of
the targeted mutation, we first excised the LSL cassette
ex vivo by adding Cre recombinase to p53LSL-D31/LSL-D31 MEFs
or to p53LSL-WT/LSL-WT MEFs (Ventura et al., 2007) as controls
(Figures 2A and 2B). Similar p53 mRNA levels were found in
the resulting p53WT/WT and p53D31/D31 MEFs, but mutant cells
contained higher mRNA levels of the p53 targets p21(Cdkn1a)
and Mdm2, indicating an increased p53 activity (Figures 2C
and 2D).Cp53+/LSL-D31 mice were also mated with PGK-Cre mice to
obtain MEFs expressing p53D31 constitutively, analyzed below.
Immunofluorescence revealed that the p53D31 protein is mostly
nuclear, more abundant than p53WT, and that it accumulates in
response to stress (Figure 2E). Western blots confirmed the
increased p53 levels in mutant cells (Figure 2F). p53D31 protein
levels were regulated by the ubiquitin ligase Mdm2, as indicated
by treatment with Nutlin, a specific Mdm2 inhibitor (Figure 2G).
The p21 and Mdm2 protein levels were increased in p53D31/D31
MEFs (Figure 2F), and both genes were transactivated more effi-
ciently in mutant cells (Figure 2H), although p53D31 did not
appear to bind specific sequences at the p21 and Mdm2
promoters more efficiently than p53WT (Figure 2I). Additional ex-
periments confirmed that p53 target genes are more efficiently
regulated in p53D31/D31 cells (Figure S2A). Mutant MEFs pre-
sented increased G1/S ratios before or after irradiation (Figures
2J and S2B) and ceased to proliferate prematurely (Figures 2K
and 2L). Together, these data demonstrated that p53D31/D31 cells
exhibit increased p53 activity.
p53D31/D31 Mice Model Telomere Syndromes
p53D31/D31 mice were born in Mendelian proportions from
p53+/D31 intercrosses, but most died 14–43 days after birth (Fig-
ure 3A). Because a mutation removing the last 31 residues of the
CTD prevents the expression of isoforms with an AS C terminus
(Figure S1B), we also generated mice with a specific deletion of
exon AS. None of these mutants died within 3 months after birth
(Figure S3), indicating that the premature death of p53D31/D31
mice does not result from a loss of p53AS isoforms. The
p53D31/D31 mice that died within a month were significantly
smaller than their littermates (Figure 3B), as reported for mice
with an increased p53 activity (Mendrysa et al., 2003; Liu et al.,
2007, 2010). Other evidence of increased p53 activity (Liu
et al., 2007; Terzian et al., 2007; McGowan et al., 2008) in
p53D31/D31 mice included darker footpads and tails (Figures 3C
and S4A), increased thymocyte apoptosis (Figures 3D and
S4B), cerebellar hypoplasia, and hypogonadism in males (Fig-
ures S4C and S4D). p53D31/D31 mice suffered from severe
pancytopenia and had hypertrophic hearts typical of anemic an-
imals (Figures 3E and 3F). A dramatic decrease in marrow cellu-
larity was observed in p53D31/D31 mice (Figure 3G), and mutant
bone marrow cells (BMCs) lacked hematopoietic progenitors
(Figures 3H, 3I, S4E, and S4F). Thus, the premature death of
most p53D31/D31 animals likely results from aplastic anemia
and consecutive heart failure, consistent with previous reports
of hematopoietic defects correlating with spontaneous perinatal
death (Liu et al., 2007, 2010), accelerated aging (Dumble et al.,
2007), or increased radiosensitivity (Mendrysa et al., 2003; Her-
rera-Merchan et al., 2010; Wang et al., 2011a) in mouse models
with increased p53 activity.
Strikingly, p53D31/D31 mice also developed pulmonary fibrosis
(Figures 4A and 4B). In humans, the association of aplastic ane-
mia and pulmonary fibrosis characterizes syndromes caused by
abnormally short telomeres (Parry et al., 2011b). We compared
the length of telomeres in WT and p53D31/D31 cells and found
shorter telomeres in mutant cells (Figures 4C and 4D). Further-
more, telomere dysfunction-induced foci were more frequent in
p53D31/D31 cells (Figure S5). This led us to conclude thatell Reports 3, 2046–2058, June 27, 2013 ª2013 The Authors 2047
Figure 1. Targeting a Deletion of the CTD at the Mouse Trp53 Locus
(A) Targeting strategy. The Trp53 gene is within a 17-kb-long EcoRI (RI) fragment (black boxes indicate coding sequences; white boxes showUTRs). The targeting
construct (above) contains (1) a 1.5-kb-long 50 homology region; (2) a LSL cassette with a neomycin selection gene (Neo), four transcriptional Stops (STOP), and a
EcoRI site, flanked by LoxP sites (arrowheads); (3) p53 exons, including the nonsensemutation in exon 10 (asterisk) and an additional Bcl I site; (4) a 2.8-kb-long 30
homology region; and (5) the diphtheria a-toxin (DTA) gene for targeting enrichment. Recombinants from the depicted crossing-overs were identified by a 2.4-kb-
longbandafterPCRwithprimers i and j, andbandsof 2.1, 1.1, and0.5kbafterPCRwithprimersgandhandBcl I digestion.Recombinant cloneswere alsoanalyzed
bySouthernblotwith the indicatedprobeascontaininga10.5 kbEcoRIband.Themutationwas routinelygenotypedbyPCRwithprimerse and f andBcl I digestion.
(B–D) Screening of recombinant clones as described in (A). ES clones were screened (asterisk [*] indicates a positive clone) by PCR with primers i and j (B), with
primers g and h, then PCR products were digested or not (b or u) with BclI (C) and by Southern blot (D).
(E) MEF genotyping by PCR.MEFs, prepared from embryos from an intercross of p53+/LSL-D31mice, were genotyped by PCRwith primers e and f followed by Bcl I
digestion.
See also Figure S1.p53D31/D31 mice model DC, an archetypal telomere syndrome
caused by mutations in genes encoding components of the telo-
merase or shelterin complexes, or telomerase regulators (Arma-
nios and Blackburn, 2012). In support of this conclusion,
p53D31/D31 mice presented full-blown clinical features of DC:
cutaneous hyperpigmentation, nail dystrophy, and oral leukopla-
kia (Figures 4E and 4F). Furthermore, the small size, hypogonad-
ism, and cerebellar hypoplasia observed in some mice (Figures
3B, S4C, and S4D) characterize patients with the Hoyeraal-Hrei-
darsson syndrome (HHS), a severe variant of DC (Armanios and
Blackburn, 2012).
DC-related featureswere also detected in p53+/D31mice: three
p53+/D31 mice died within a year with a hypertrophic heart (Fig-
ure 5A). Moreover, heterozygous mutants with lower levels of2048 Cell Reports 3, 2046–2058, June 27, 2013 ª2013 The Authorsp53-negative regulators (i.e., most p53+/D31 Mdm4+/ and a
few p53+/D31 Mdm2+/ mice) died within 3 months (Figure 5B).
This suggested that the levels of p53 inhibitors—particularly
Mdm4—impacted the severity of DC-related symptoms.
Accordingly, bone marrow cellularity and telomere length were
decreased in p53+/D31 Mdm4+/ mice compared to p53+/D31
mice (Figures 5C, 5D, and S6).
p53 Activation Alters the Expression of Genes Mutated
in Telomere Syndromes
Animal models recently suggested that dysfunctional telomeres
(Wang et al., 2011b) or altered ribosomal RNA processing (Pere-
boom et al., 2011) could lead to p53 activation and bone marrow
failure. Our data suggested that a p53-truncating mutation might
Figure 2. p53D31/D31 MEFs Exhibit Increased p53 Activity
(A) Strategy to analyze the effects of an excision of the LSL cassette ex vivo. A His-tagged NLS-Cre recombinase (HTN-Cre) was added to p53LSL-D31/LSL-D31
MEFs, allowing excision of the Stop cassette within 24 hr. p53D31/D31 MEFs were then recovered and analyzed (right). As controls, p53LSL-WT/LSL-WT MEFs were
treated likewise (left). p53LSL-D31/LSL-D31 MEFs were also treated with a buffer solution devoid of Cre as negative controls (center).
(B) Efficiency of the Cre-mediated excision of the LSL cassette. LSL excision was determined using multiplex PCR with primers k, l, and m. Prior excision, a 278-
bp-long product results from amplificationwith primers k and l, whereas primersm and l are too far apart to generate a PCRproduct. After excision, primersm and
l generate a 330-bp-long product. The PCR analysis of the experiment described in (A) is shown: PCRs show100%efficiency in LSL excision (Exc.) in lanes a, d,
and e; and 0% in lanes b and c.
(C and D) p53LSL-D31/LSL-D31 MEFs exhibit increased p53 activity after LSL excision. mRNAs were prepared from p53LSL-WT/LSL-WT MEFs treated with HTN-Cre (a)
or p53LSL-D31/LSL-D31 MEFs treated with buffer (b and c) or HTN-Cre (d and e). p53 mRNAs (C) or p21 and Mdm2mRNAs (D) were quantified using real-time PCR,
normalized to control mRNAs, then the amount in (a) was assigned a value of 1.
(E–L) Comparative analysis of WT and p53D31/D31 MEFs.
(E) WT and p53D31/D31 (D31/D31) MEFs untreated (Unt) or treated with 0.5 mg/ml Adriamycin (Adr) for 24 hr were stained with a p53 antibody, and their DNA was
counterstained with DAPI.
(legend continued on next page)
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be sufficient to cause bone marrow failure but also typical DC
features including short telomeres and oral leukoplakia (Table
1). Laboratory mice have long telomeres, andmice that lack telo-
merase exhibit short telomeres only after several generations of
intracrosses (Blasco et al., 1997). However, mice with a telome-
rase haploinsufficiency and a deficient shelterin complex exhibit
telomere dysfunction in a single generation (G1) (Hockemeyer
et al., 2008; He et al., 2009). The short telomeres in G1
p53D31/D31 mice thus suggested a pleiotropic effect of p53 on
telomere metabolism.
Although p53 may regulate TRF2 via the ubiquitin ligase Siah1
(Fujita et al., 2010), a link between p53 and genes mutated in DC
appeared most likely for TCAB1/WRAP53 because this gene
partially overlaps TP53 (Zhong et al., 2011). However, we found
no evidence of decreased Tcab1 expression in p53D31/D31 cells
(Figure 6A). We next quantified the mRNAs for nine other genes
known to cause DC or implicated in aplastic anemia in p53/,
WT, and p53D31/D31 cells and obtained evidence of modest but
significant decreases in the expression of Dyskerin (Dkc1),
Rtel1, Tinf2, and Terf1 in p53D31/D31 cells (Figures 6B and 6C).
Consistent with this, p53 activation led to the downregulation
of the four genes, with a stronger effect on Dkc1 (Figure 6D).
Interestingly, mice in this study were of mixed genetic back-
ground (75% C57Bl/6J; 25% 129S2/SvPas). The coat color of
inbred C57Bl/6J (B6) mice is black, whereas that of 129S2/
SvPas (129) is agouti because these strains carry nonagouti (a)
or agouti (Aw) alleles, respectively. We noticed that most
p53D31/D31 mice alive after 3 months (Figure 3A) had an agouti
coat color and, conversely, that the few p53+/D31 mice that
died in less than a year (Figure 5A) had a black coat color. These
observations suggested that a gene physically linked to the Aw/a
locus had an impact on the survival of p53D31 mutants and that
the 129 allele for this gene correlated with a better survival.
Rtel1 appeared as a candidate gene because it is a dominant-
positive regulator of telomere length (Ding et al., 2004) that
maps 26 cM away from the Aw/a locus. We used a SNP within
the Rtel1 intron 15 (rs33116597) that differs between the B6
and 129 strains to genotype Rtel1 alleles in a cohort of 52
p53D31/D31 mice and found a significant increase in survival for
p53D31/D31 mice carrying 129 Rtel1 allele(s) (Figures 6E and
6F). Importantly, when we quantified Rtel1 mRNA levels in
BMCs of the C57Bl/6J and 129S2/SvPas pure inbred strains,
we found increased levels in 129 cells (Figure 6G). Together,
these results suggest that basal levels of Rtel1 mRNAs may
affect the severity of phenotypes caused by the p53D31mutation.(F) Protein extracts, prepared from indicated MEFs untreated or treated as in (E),
quantification revealed that unstressed p53D31/D31 MEFs contained three to thre
(G) p53D31/D31 MEFs were untreated or treated with 10 mM Nutlin for 24 hr before
(H) mRNAs from indicated MEFs were quantified as in (C), and amounts in unstre
(I) ChIP assay was performed for p53-binding sites and nonbinding sites at the p
phosphorylated serine 18 or rabbit IgG as a negative control. Immunoprecipitates
over an irrelevant region.
(J) Cell-cycle control was analyzed in asynchronous cell populations 24 hr after 0
(K) p53D31 leads to a decreased proliferation capacity in a 3T3 protocol. The pro
Each point is a mean value from two independent MEFs, the value for each MEF
(L) Senescence-associated b-galactosidase staining of p53/, WT, and p53D31/
Mean + SEM from three or more experiments are shown in all figures. ***p% 0.0
See also Figure S2.
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Dkc1, Rtel1, Tinf2, and Terf1 genes. Because p21 levels are
known to contribute to the p53-mediated downregulation of
many genes (Lo¨hr et al., 2003), we tested if p53 could downregu-
late these genes in p21/ MEFs. We found that p21 is required
for the p53-mediated downregulation of Rtel1, Tinf2, and Terf1,
but not Dkc1 (Figure 6H). This suggested a more direct mecha-
nism for the downregulation of Dkc1. Consistent with this, Dkc1
was efficiently downregulated after treating WT cells with Nutlin
for only 6 hr, whereas for the other genes, we observed a partial
downregulation after 6–9 hr of Nutlin and a more efficient down-
regulation after 24 hr of Nutlin (Figure 6I). Furthermore, chro-
matin immunoprecipitation (ChIP) experiments provided direct
evidence that p53 binds the Dkc1 promoter (Figures 6J–6K).
In summary, we found that a nonsensemutation in the exon 10
of Trp53, encoding the truncated protein p53D31, causes an in-
crease in p53 activity and phenotypes related to human telomere
syndromes. To perform a more comprehensive analysis of
nonsense mutations affecting Trp53 exon 10, we also targeted
in MEFs mutations encoding p53D36, p53D45, or p53D52 and
found that only the latter two mutations led to measurable
decreases in p53 mRNAs and activity (Figures S7A–S7G).
Strikingly, the nonsense mutations affecting human TP53 exon
10 that were reported in cancers also cause the loss of at least
45 residues, suggesting that our finding inmicemight be relevant
to humans (Figure S7H). Given that decreased dyskerin levels
may cause short telomeres (Parry et al., 2011a), that Rtel is
a major determinant of telomere length (Ding et al., 2004), and
that mutations in DKC1 or RTEL1 are found in a significant
fraction of patients with DC or HHS (Armanios and Blackburn,
2012; Ballew et al., 2013; Walne et al., 2013), it was important
to test whether or not p53 downregulates these genes in human
cells. We compared human primary WT cells with p53-deficient
cells and observed that the activation of human p53 also leads to
the downregulation of DKC1 and RTEL1 (Figures 6L and 6M).
Our finding that p53 downregulates these genes in both species
strengthens the notion that p53 plays a significant role in the
regulation of telomere metabolism.
DISCUSSION
A Targeted Deletion of the p53 CTD Leads to Increased
p53 Activity
In this report, we targeted a nonsense mutation at the murine
Trp53 locus to analyze the consequences of a deletion of thewere immunoblotted with antibodies against Mdm2, p53, p21, and actin. Band
e and a half times more p21 or Mdm2 proteins than unstressed WT cells.
protein extraction.
ssed WT cells were assigned a value of 1. Nutl, Nutlin.
21 and Mdm2 loci in Adriamycin-treated MEFs with an antibody against p53
were quantified using real-time PCR. Fold enrichments were normalized to data
, 3, or 12 Gy g-irradiation.
liferation of p53/ (KO), WT, and p53D31/D31 (D31/D31) MEFs was compared.
resulting from triplicate plates.
D31 MEFs at passage 8.
01; **p% 0.01; *p% 0.05; n.s., not significant by Student’s t test.
Figure 3. Increased p53 Activity and Aplastic Anemia in p53D31/D31 Mice
(A) Survival of WT, p53+/D31 (+/D31), and p53D31/D31 (D31/D31) mice over 90 days. Cohort sizes are in parentheses.
(B) Examples of 28-day-old (P28) WT, p53+/D31, and p53D31/D31 littermates.
(C) Photographs of legs and tails of the samemice. Compared to theWT, the heterozygote has a slightly darker pigmentation of the palm and tail. The homozygote
mutant has a much darker pigmentation, which includes footpads.
(D) Comparative analysis of hematoxylin and eosin staining (H&E) of the thymus of WT andmutant P23 littermates, showing an increased spontaneous apoptosis
in the mutant.
(E–I) p53D31/D31 mice suffer from aplastic anemia.
(E) Hemograms from p53D31/D31 and WT mice. WBC, white blood cells; RBC, red blood cells; PLT, platelets. All mice were 3–4 weeks old when their hemogram
was determined, except for mouse D31/D31 #5, moribund at 19 days, which was analyzed and euthanized on the same day.
(F) Mutant mice present enlarged hearts upon dissection. Top view shows example of hearts from WT and p53D31/D31 P18 littermates. Bottom view illustrates
heart/total body weight ratios determined for nine WT and ten p53D31/D31 age-matched animals.
(G) H&E of sternum sections from WT and p53D31/D31 P23 littermates.
(H) BMCs, stained with antibodies against hematopoietic lineage (Lin) markers and cell surface marks Sca1 and c-Kit, were analyzed by flow cytometry. The
population of Lin Sca1+ c-Kit+ (LSK) cells, enriched in hematopoietic stem cells, were calculated as percentage (%) of total mononucleated cells (MNCs).
Results are from three mice per genotype.
(I) BMCs (1 or 23 106) fromWT or p53D31/D31 donor mice expressing the leukocytemarker CD45.2 were transplanted into lethally irradiated recipient mice (initially
expressing marker CD45.1). Transplanted WT cells, but not p53D31/D31 cells, rescued the irradiated animals by repopulating the bone marrow. Results are from
five mice per genotype. BMT, bone marrow transplant.
Mean + SEM are shown in (F) and (H). *** p% 0.001, Student’s t test.
See also Figures S3 and S4.
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Figure 4. p53D31/D31 Mice Exhibit Features Specific to DC
(A and B) Pulmonary fibrosis in p53D31/D31 mice. Masson’s trichrome staining of lungs fromWT and p53D31/D31 mice, shown at different magnifications. Interstitial
fibrosis, characterized by deposits of collagen (stained in green), is increased in the mutant.
(C and D) p53D31/D31 cells have short telomeres. In (C), telomere lengthwas analyzed in BMCs using flow-FISHwith a telomere-specific PNA probe. On top, typical
results with P18 littermate mice are shown (>2,100 cells per sample, from a WT and a p53D31/D31 mouse). For each animal, histograms on the right show green
fluorescence (Fluo.), with black histograms for cells without the probe (measuring cellular autofluorescence), and green histograms for cells with the probe. The
shift in fluorescence intensity is smaller in mutant cells (b < a), indicating reduced telomere length. Histograms on the left show propidium iodide fluorescence
(superposed for cells with or without the probe). Bottom row presents results from four animals per genotype. Mean + SEM are shown. ***p% 0.001, Student’s
(legend continued on next page)
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Figure 5. p53+/D31 Mice Are Extremely Sensitive to Mdm4 Levels
(A) Survival of WT (+/+) and p53+/D31 (+/D31) mice over 1 year, plotted as in
Figure 3A.
(B) Survival of p53+/D31, Mdm2+/ (M2+/), Mdm4+/ (M4+/), p53+/D31
Mdm2+/ (+/D31 M2+/), and p53+/D31 Mdm4+/ (+/D31 M4+/) mice over
3 months.
(C) H&E of sternum sections from p53+/D31 and p53+/D31 Mdm4+/ littermates.
(D) Telomere length was measured by flow-FISH as described in Figure 4C, in
BMCs fromWT, p53+/D31, Mdm4+/, and p53+/D31 Mdm4+/mice. Results are
from three animals per genotype.
Mean + SEM are shown. ***p% 0.001, Student’s t test.
See also Figure S6.p53 C-terminal domain ex vivo and in vivo. The mutation led to
increased p53D31 levels, consistent with in vitro studies that
concluded that the p53 CTD is required for an optimal interaction
between p53 and its ubiquitin ligase Mdm2 (Poyurovsky et al.,
2010). Cells expressing p53D31 also exhibited increased p53 ac-
tivity, despite the fact that the binding of the mutant protein to
target gene promoters was not significantly increased. Thus,
as earlier observations suggested (Kaeser and Iggo, 2002; Espi-
nosa, 2008), the induction of a p53 target gene is not simply
determined by the amount of p53 bound to its promoter. Pre-t test. In (D), telomere length was analyzed in WT or p53D31/D31 MEFs at passage
typical metaphases are shown. In the mutant cells, several chromosomes exhi
analysis of 28 metaphases per genotype are shown.
(E and F) p53D31/D31 mice exhibit the triad of physical traits classically used to di
(E) Cutaneous hyperpigmentation and nail dystrophy on a p53D31/D31 hindleg. Ar
(F) H&E comparison of the dorsal surface of a WT and a p53D31/D31 tongue. Th
leukoplakia.
See also Figure S5.
Csumably, the deletion of the p53 CTDmight activate transcription
by affecting p53-Mdm2 interactions (Poyurovsky et al., 2010)
and/or by preventing the formation of p53CTD-Mediator inactive
complexes (Meyer et al., 2010).
Our observation that a p53 mutant lacking the CTD exhibits
increased activity may seem surprising when compared to
recent studies relying on ectopically expressed human p53
CTD mutants, which concluded that the CTD mainly acts as a
positive regulator of p53 functions (Hamard et al., 2012; Kim
et al., 2012). Importantly, however, these studies analyzed WT
and mutant p53 expressed at equal levels, whereas we showed
here that a targeted CTD deletion leads to mutant protein accu-
mulation. In that respect, it is worth considering that despite its
increased nuclear abundance, p53D31 did not exhibit an
increased binding at p53 target gene promoters. This may sug-
gest that, on a per molecule basis, p53D31 is less efficient than
WT p53 for sequence-specific DNA binding, consistent with
other studies (McKinney et al., 2004; Tafvizi et al., 2011). There-
fore, it appears likely that if p53D31 had been expressed at similar
levels thanWT p53 in themutant cells, the overall increase in p53
activity would not have been observed. Our observations thus
suggest that differences in expression levels might underlie
much of the contradictions in the p53 CTD literature.
p53 Mutations Affecting the CTD Model Telomere
Syndromes
Germline missense TP53 mutations affecting the core DNA-
binding domain are well known to cause the cancer-prone Li-
Fraumeni syndrome in humans (Malkin et al., 1990; Srivastava
et al., 1990), and mice with equivalent p53 mutations may, like
patients with Li-Fraumeni, develop osteosarcomas (Lang et al.,
2004; Olive et al., 2004). In striking contrast, we found here
that mice homozygous for a germline nonsense mutation
affecting the p53 CTD, or compound heterozygotes with a
Mdm4 haploinsufficiency, are remarkable models of human telo-
mere syndromes. In murine cells, p53 activation led to the down-
regulation of four genes including Dyskerin (Dkc1), a gene often
mutated in patients with DC (Armanios and Blackburn, 2012).
Importantly, in addition to its role as a telomerase component,
dyskerin acts as a pseudouridine synthase in snoRNP com-
plexes. This might explain why patients with DC carrying DKC1
mutations exhibit more clinical features than patients carrying
TERC mutations (Vulliamy et al., 2011). Similarly, some of the
DC features observed in p53D31/D31 mice might result from p53
activation or Dkc1 downregulation, rather than telomere
dysfunction per se. However, decreased telomere length likely
played a role in the premature death of p53D31/D31 mice because
we found strain-specific differences in Rtel1 mRNA levels to
correlate with differences in the survival of mutant mice.5 by quantitative FISH with a telomere-specific Cy3 PNA probe (in red). On top,
bit faint or no visible telomeric signals. Below, quantification results from an
agnose DC.
row points to the dystrophic nail.
e mutant tongue exhibits acanthosis and hyperparakeratosis, typical of oral
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Table 1. Features of DC in p53D31/D31 Mice and in Other Reported Mice with Altered p53 Regulation or Dysfunctional Telomeres
Clinical Features in Patients
Diagnosed with DC
Observed in p53D31/D31 Mice %
Animals with Feature (No. Analyzed)
Observed in Other Mice
with Altered p53 Regulationa Observed in Mouse Models of DCb
Physical Traits (Diagnostic Triad)c
Skin hyperpigmentation ✔ 100% (25) ✔ ✔
Nail dystrophy ✔ 8% (25) Not reported ✔
Oral leukoplakia ✔ 100% (8) Not reported Not reported
Pathological Traitsd
Bone marrow failure ✔ 100% (8) ✔ ✔
Pulmonary fibrosis ✔ 87% (8) Not reported Not reported
Molecular Featuree
Poor telomere maintenance ✔ 100% (4) Not reported ✔
Associated Featuresf
Hypertrophic heart ✔ 100% (25) ✔ Not reported
Short stature ✔ 63% (25) ✔ ✔
Testicular atrophy ✔ 91% (11) ✔ ✔
Cerebellar hypoplasia ✔ 30% (10) ✔ Not reported
The features used to diagnose DC are indicated in bold. p53+/D31 Mdm4+/mice, not included in this table, exhibited the same features as p53D31/D31
mice. Likewise, p53D31/D31 MEFs exhibited short/dysfunctional telomeres but were not included in this table.
aMice with altered p53 regulation include mutants with severe decreases in Mdm2 levels (Mendrysa et al., 2003; Liu et al., 2007), combined Mdm2 and
Mdm4 haploinsufficiencies (Terzian et al., 2007), complex p53 mutations (McGowan et al., 2008; Liu et al., 2010; Wang et al., 2011a), or constitutive
cellular stress (McGowan et al., 2008).
bPreviously reported mouse models of DC combined a Pot1b deficiency with a telomerase RNA haploinsufficiency (Hockemeyer et al., 2008; He et al.,
2009).
cDC is classically diagnosed when at least two of these physical features are observed.
dInherited bone marrow failure is found in other syndromes (e.g., Blackfan-Diamond anemia, Fanconi anemia), but the combination of bone marrow
failure and pulmonary fibrosis characterizes DC (Parry et al., 2011b).
eTelomeres are often analyzed to diagnose DC.
fThese features can be found in patients with DC but are not specific enough for diagnosis.Importantly, p53+/D31 mice were mildly affected: they pre-
sented only slight alterations (if any) in HSC pools and telomere
length, and most were alive for more than 12 months. Because
p53D31/D31 and p53+/D31 Mdm4+/ mice developed full-blown
DC features, we conclude that a%2-fold difference in p53 activ-
ity was sufficient to prevent the observation of DC features in het-
erozygous mice. This observation might explain why mouse
models with modest increases in p53 activity were only found
to present slight alterations in HSC pools (e.g., Herrera-Merchan
et al., 2010).
An important remaining question is whether germline p53 mu-
tations affecting the CTDmay lead to telomere syndromes in hu-
mans. The high degree of conservation between the human and
murine p53 CTDs, the comparison of phenotypes caused by
nonsense mutations in the exon 10 of the human and mouse
p53 genes, and the fact that p53 activation also leads to the
downregulation of DKC1 and RTEL1 in human cells together
support this possibility. Importantly, genes presently known to
cause DC account for about only half of the clinical cases, and
patients with DC are now thought to represent a small fraction
of persons suffering from a telomere syndrome (Armanios and
Blackburn, 2012). Although one should be careful about extrap-
olating mouse data to human diseases, our results lead us to
propose that TP53 (and possibly MDM4) should be sequenced
in patients with telomere syndromes of currently unknown mo-
lecular origin.2054 Cell Reports 3, 2046–2058, June 27, 2013 ª2013 The AuthorsEXPERIMENTAL PROCEDURES
Cells and Cell Culture Reagents
MEFs isolated from 13.5-day embryos were cultured in a 5% CO2 and 3% O2
incubator, in DMEM GlutaMAX (Gibco), with 15% FBS (Biowest), 100 mM 2-
mercaptoethanol (Millipore), 0.01 mM Non-Essential Amino-Acids, and peni-
cillin/streptavidin (Gibco) for six or less passages, except for 3T3 experiments,
performed in a 5% CO2 incubator for eight passages. Human lung fibroblast
MRC5 and its SV40-transformed derivatives were cultured in a 5% CO2 and
3% O2-regulated incubator in MEM (Gibco), completed with 10% FBS,
2mML-glutamine (Gibco), 1 mMpyruvate, 10 mMNon-Essential Amino-Acids,
and penicillin/streptomycin. Cells were irradiated with a Cs g-irradiator or
treated with Adriamycin (Sigma-Aldrich) at 0.5 mg/ml or 10 mM Nutlin 3a
(Sigma-Aldrich).
Quantitative RT-PCR
Total RNA, extracted using NucleoSpin RNA II (Macherey-Nagel), was reverse
transcribed using SuperScript III (Invitrogen). Real-time quantitative PCRs
(primers available upon request) were performed on an ABI PRISM 7500 using
Power SYBR Green (Applied Biosystems). For strain-specific Rtel1 expression
analysis, total mRNAs were extracted from the BMCs of inbred C57Bl/6J and
129S2/SvPasmice (Charles River Laboratories), and Rtel1mRNAs were quan-
tified as above.
LSL-D31 Construct
We used mouse genomic p53 DNA from previous constructs (Toledo et al.,
2006a, 2006b) and a portion of intron 1 containing a LoxP-Stop-LoxP (LSL)
cassette (Ventura et al., 2007) in which the puromycin-resistance gene was re-
placed by a neomycin gene (details available upon request). A BsrG I site (in
intron 9) and a Fse I site (inserted downstream Trp53) were used to swap
(legend on next page)
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the nonsense mutation from the p53D31 RMCE-ASAP construct (Extended
Experimental Procedures) in the LSL-targeting construct. The resulting LSL-
p53D31-targeting vector was fully sequenced before use.
Targeting in ES Cells and Genotyping
CK-35 ES cells were electroporatedwith the targeting construct linearized with
Not I. Two independent recombinant clones, identified by long-range PCR and
confirmed by Southern blot and PCR, were injected into blastocysts to
generate chimeras, and germline transmission was verified by genotyping
MEFs from their offspring. RT-PCR of RNAs from p53LSL-D31/LSL-D31 MEFs
treated with HTN-Cre showed that the mutant cDNA differed from a p53WT
sequence only by the engineered nonsense mutation. Primers for Trp53 and
Rtel1 genotyping are available upon request. All experiments were performed
according to IACUC regulations.
LSL Cassette Excision
Triplicates of 1.8 3 105 p53LSL-WT/LSL-WT (Ventura et al., 2007) and
p53LSL-D31/LSL-D31 MEFs were seeded in wells of a 6-well plate and treated
with 10 mM HTN-Cre for ex vivo excision of the LSL cassette or 105 cells
with buffer only. After 24 hr, wells were washed, and cells were frozen when
reaching 90% confluence. Cells were then thawed for DNA and RNA extrac-
tions to determine excision efficiency and for mRNA quantifications. In vivo
LSL excision was performed by breeding with PGK-Cre mice.
Immunofluorescence
MEFs were cultured on collagen-coated coverslips, exposed to Adriamycin,
and analyzed 24 hr later. Coverslips were stained with the p53 antibody CM-
5 (Novocastra) and secondary Alexa Fluor 488 anti-mouse antibody (Molecular
Probes). Imageswere captured on an epifluorescencemicroscope using equal
exposure times for all images for each fluor.Figure 6. p53 Activation Leads to the Downregulation of Genes Involve
(A) Tcab1 mRNA levels are not altered in p53D31/D31 cells. RNAs, prepared from
Nutlin for 24 hr, were used to quantify Tcab1/Wrap53 mRNAs. Results are from
(B) Evidence of decreased mRNA levels for Dkc1, Rtel1, Tinf2, and Terf1 in un
p53D31/D31 MEFs, were used to compare the expression of eight genes known to c
(Terf1) that has been implicated in aplastic anemia, a milder form of telomere sy
periments were analyzed by one-way ANOVA.
(C) p53D31/D31 cells contain decreased levels of the dyskerin and Rtel proteins. P
with antibodies against Rtel, dyskerin (dysk), and actin.
(D)Dkc1, Rtel1, Tinf2, and Terf1 are downregulated by murine p53. mRNAs for Dk
untreated or treated with 10 mM Nutlin for 24 hr. Results are from four independe
(E–G) Improved survival of p53D31/D31 mice carrying 129S2/SvPas Rtel1 allele(s).
(E) DNA was extracted from 52 p53D31/D31 mice of mixed genetic background, the
were digested with EcoNI to genotype 129S2/SvPas (129) and C57Bl/6J (B6) Rte
analysis of four mice is shown, with Rtel1 genotypes above the gel.
(F) Survival of p53D31/D31 mice taking Rtel1 genotyping into account. Cohort size
(G) Comparison of Rtel1 mRNA levels in the BMCs of 129S2/SvPas (129) and C5
(H) p21 is required for the downregulation ofRtel1, Tinf2, and Terf1. RNAs, prepare
24 hr, were used to quantify Dkc1, Rtel1, Tinf2, and Terf1 mRNAs. Results are fr
(I) p53 activation rapidly leads to the efficient downregulation of Dkc1. mRNAs for
with 10 mM Nutlin for 6, 9, 12, or 24 hr. Results are from two independent experi
(J and K) p53 regulates the Dkc1 promoter.
(J) ChIP assay was performed at ten different sites surrounding the Dkc1 mRNA tr
using a polyclonal antibody against p53 (FL-393) or rabbit IgG as a negative contr
were normalized to data over an irrelevant region. Indicated values are means fr
suggest p53 binding near the end of exon 1 (E1) of Dkc1.
(K) Data from three independent ChIP experiments focusing on the end of Dkc1
(L and M) Dyskerin and Rtel are also downregulated by p53 in human cells.
(L) Protein extracts, prepared from WT MRC5 human cells (MRC) and p53-deficie
dyskerin, and actin.
(M) mRNAs were prepared from SV40-MRC5 andMRC5 human cells, untreated o
time PCR, normalized to control mRNAs, and mRNA ratios from Nutlin-treated
periments.
Mean + SEM are shown. ***p% 0.001; **p% 0.01; *p% 0.05; n.s., not significan
See also Figure S7.
2056 Cell Reports 3, 2046–2058, June 27, 2013 ª2013 The AuthorsWestern Blots
Protein detection by immunoblotting was performed using antibodies against
p53 (CM-5, Novocastra; or FL-393, Santa Cruz Biotechnology), actin (A2066;
Sigma-Aldrich), p21 (F5; Santa Cruz Biotechnology), and Mdm2 (4B2), Rtel1
(MP1), and Dyskerin (H-300; Santa Cruz Biotechnology). Chemiluminescence
revelation was achieved with SuperSignal West Dura (Perbio). Bands of inter-
est were quantified by using ImageJ and normalized with actin.ChIP Assay
ChIP analysis was performed as described (Simeonova et al., 2012). p53-DNA
complexes were immunoprecipitated from total extracts by using 5 mg of an
antibody against mouse Phospho-p53 Ser18 (Cell Signaling Technology)
and 15–30 mg of sonicated chromatin, or 50 mg of a polyclonal antibody against
p53 (FL-393) and 300 mg of sonicated chromatin. Rabbit IgG (Abcam) was
used for control precipitation. Quantitative PCR was performed on ABI PRISM
7500.Cell-Cycle Assays
Log phase cells were irradiated at RT with a Cs g-irradiator at doses of 3 or
12 Gy, incubated for 24 hr, then pulse labeled for 1 hr with BrdU (10 mM),
fixed in 70% ethanol, double stained with FITC anti-BrdU and propidium
iodide, and sorted by using a BD Biosciences FACSort. Data were analyzed
using FlowJo.Anatomopathology
Organs were fixed in formol 4% for 24 hr, then ethanol 70%, and embedded in
paraffin wax. Serial sections were stained with hematoxylin and eosin or Mas-
son’s trichrome using standard procedures (Prophet et al., 1992).d in Telomere Metabolism
p53/ (KO), WT, and p53D31/D31 (D31) MEFs, untreated or treated with 10 mM
four independent experiments.
stressed p53D31/D31 cells. RNAs, prepared from unstressed p53/, WT, and
ause DC (Ctc1, Dkc1,Nhp2, Nop10, Rtel1, Terc, Tert, and Tinf2) and one gene
ndrome (Armanios and Blackburn, 2012). Results from four independent ex-
rotein extracts, prepared from WT and p53D31/D31 MEFs, were immunoblotted
c1, Rtel1, Tinf2, and Terf1 were quantified in p53/, WT, and p53D31/D31 MEFs,
nt experiments. p = 0.0545.
n PCRwas performed with primers flanking the SNP rs33116597, and products
l1 alleles because only the B6 PCR products contained an EcoNI site. A typical
s are in parentheses. The p value is from a log rank test.
7Bl/6J (B6) mice. Results are from four mice per strain.
d fromWT and p21/ (p21) MEFs, untreated or treated with 10 mMNutlin for
om three independent experiments.
Dkc1, Rtel1, Tinf2, and Terf1 were quantified in WTMEFs, untreated or treated
ments.
anscription start site (TSS) in Adriamycin-treatedWT and p53/ (KO) MEFs by
ol. Immunoprecipitates were quantified using real-time PCR. Fold enrichments
om two independent ChIP experiments, each quantified in triplicates. Results
exon 1 confirm significant p53 binding.
nt SV40-MRC5 cells (SVM), were immunoblotted with antibodies against Rtel,
r treated with Nutlin, then DKC1 and RTEL1 mRNAs were quantified using real-
versus untreated cells were determined. Results from three independent ex-
t by Student’s t test.
Hemograms
For each animal, 100 ml of blood was recovered retro-orbitally in a 10 ml citrate-
concentrated solution (S5770; Sigma-Aldrich) and analyzed using a MS9 ma-
chine (Melet Schloesing Laboratory).
Hematopoietic Marker Analysis
BMCswere flushed from femurs and tibias of age-matchedWT and p53D31/D31
mice, then incubated with FITC-labeled antibodies against markers Gr1, B220,
Ter119, TCR, CD19, Dx5, CD11b, CD4, and CD8, PE-conjugated anti-Sca1
and APC-conjugated anti-CD117, then analyzed using FlowJo.
Long-Term Reconstitution Assay
Donor BMCs were isolated from WT or p53D31/D31 littermate mice (Ly5.2) and
retro-orbitally injected into lethally irradiated Ly5.1 recipients, 4 hr post 12 Gy
irradiation. Six weeks posttransplant, reconstitution of donor leukocytes was
analyzed by staining blood cells with antibodies against leukocyte cell surface
markers CD45.1 (BD PharMingen) and CD45.2 (BioLegend) and flow
cytometry.
Telomeric Flow-FISH
Flow-FISH was performed as described by Baerlocher et al. (2006). For each
animal, the bone marrow from two tibias and two femurs was collected, red
blood cells were lysed, then 23 106 cells were fixed in 500 ml PNA hybridization
buffer (70% deionized formamide, 20 mM Tris [pH 7.4], 0.1% Blocking re-
agent; Roche) and stored at20C. Either nothing (control) or 5 ml probe stock
solution was added to cells (probe stock solution: 10 mMTelC-FAMPNA probe
[PANAGENE], 70% formamide, 20 mM Tris [pH 7.4]), and samples were dena-
tured for 10 min at 80C before hybridization for 2 hr at RT. After three washes,
cells were resuspended in PBS 13, 0.1% BSA, RNase A 1,000 U/ml, propi-
dium iodide 12.5 mg/ml, and analyzed with a FACSCalibur.
Telomeric Quantitative FISH
Cells were treated with 0.5 mg/ml colcemide for 1.5 hr, submitted to hypotonic
shock, fixed in a (3:1) ethanol/acetic acid solution, and dropped onto glass
slides. Q-FISH was then carried out as described (Ourliac-Garnier and Lon-
don˜o-Vallejo, 2011) with a TelC-Cy3 PNA probe (PANAGENE). Images were
acquired using a Zeiss Axioplan 2, and telomeric signals were quantified
with iVision (Chromaphor).
Statistical Analyses
The Student’s t test was used in all figures to analyze differences between two
groups of values. In Figure 6B, differences among three groups were analyzed
by one-way ANOVA. In Figure 6F, a log rank test was used to analyze survival
curves. Analyseswere performed by usingGraphPad Prism, and values of p%
0.05 were considered significant.
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